Overactive Bladder Treatment Market Analysis by Disease Type (Neurogenic, and Idiopathic Bladder Overactivity); and by Drug Type (Darifenacin, Anticholinergics, Oxybutynin, Solifenacin, and Others)-Global Supply & Demand Analysis & Opportunity Outlook 2023-2033

  • Product Code:
    RP-ID-10059482
  • Published Date:
    21 Oct 2022
  • Region:
    Global
  • Category:
    Healthcare & Pharmaceuticals
  • Publisher:
    Pub-ID-54

Impact Analysis on the Growth of Market

Inflation and Looming Recession to Haunt Businesses:

In 2022 & 2023, market players expected to sail in rough waters; might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain. Further, U.S. economy is expected to grow merely by 3% in 2022.

..

..

The Research Report is Updated with 2022 Base Year, 2023 Estimated year and Forecast till 2035 with Market Insights.


With the dip in global production, the GDP has contracted in 2020 and impacted the market across the world. Upon placing a Sample Request, you will receive an updated report with 2022 as base year, 2023 as estimated year and forecast to 2035. This will have market drivers, recovery rate in the market, insights and competitive analysis.



Market Overview:

Translate Report

Overactive Bladder Treatment Market Scope Report

 

 Base Year 

2022

Forecast Year

2023-2033

CAGR

~5%

Base Year Market Size (2022)

 ~ USD 4.0 Billion

Forecast Year Market Size (2033)

~ USD 9.0 Billion

Global Overactive Bladder Treatment Market Highlights Over 2023 - 2033

The global overactive bladder treatment market is estimated to garner a revenue of USD 9.0 Billion by the end of 2033 by growing at a CAGR of ~5% over the forecast period, i.e., 2023 – 2033. Further, the market generated a revenue of USD 4.0 Billion in the year 2022. The growth of the market can be attributed to the increasing number of people dealing with overactive bladder. Nearly 7 Million people in the United Kingdom have urinary incontinence in the year 2019.

 

Overactive-Bladder-Treatment-Market

 

GET A SAMPLE COPY OF THIS REPORT

 

Overactive bladder (OAB) refers to a condition in which a person's need to urinate is so frequent that it negatively affects their life. There are many causes that account for overactive bladder, such as infection, nerve damage, abdominal trauma, and others. The drugs that help for the treatment of the patients includes darifenacin, anticholinergics, oxybutynin, solifenacin, and others. Moreover, there has been continuous efforts by the pharmaceutical industry to find out new innovative treatments for the overactive bladder. Therefore, the growth of pharmaceutical industry is anticipated to increase the growth of the global overactive bladder treatment market. As per the India Brand Equity Foundation, foreign direct investment in drugs and pharmaceuticals accounted for USD 19.41 Billion in between April 2000 -March 2022.

Global Overactive Bladder Treatment Market: Growth Drivers and Challenges

Growth Drivers

  • Surging Kidney Related Disorders– The urge to urinate can be increased owing to kidney problems such as when the kidney filters are damaged. Hence, it is expected to boost the growth of the global overactive bladder treatment market. As per the report stated by the Centers, more than 37 Million people accounted to have chronic kidney diseases.

  • Growing Geriatric Population – According to the data reported by the World Health Organization, 1 in 6 people around the world will be aged 60 years or above by the end of 2031.

  • Rising Prevalence of Chronic Diseases– As per the World Health Organization, nearly 422 Million people across the globe have diabetes.

  • Rising Research & Development Expenditure – According to the World Bank, research and development expenditure has increased from 2.05 per cent of GDP in 2000 to 2.63 per cent of GDP in 2020.

Challenges

  • Lack of Awareness Related to Overactive Bladder

  • Scarcity of Skilled Medical Professionals

  • High Cost for the Treatment

The global overactive bladder treatment market is segmented and analyzed for demand and supply by disease type into neurogenic, and idiopathic bladder overactivity. Out of these, the neurogenic bladder overactivity segment is anticipated to hold the largest share over the forecast period owing to the high prevalence of neurogenic bladder disorders across the globe. For instance, neurogenic bladders are found in nearly 40 t0 90 per cent of patients with multiple sclerosis and 15 per cent of all stroke patients in the United States.

Global Overactive Bladder Treatment Market Regional Synopsis

Regionally, the global overactive bladder treatment market is studied into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Amongst these markets, the market in the North America region is projected to hold the largest market share by the end of 2033 on the back of an increasing incidence of patients dealing with overactive bladder, and rising reimbursement policies for the treatment. As per the Urology Care Foundation, nearly 40 per cent women and 30 per cent men live with overactive bladder symptoms in the United States.

Market Segmentation

Our in-depth analysis of the global overactive bladder treatment market includes the following segments:

By Disease Type

  • Neurogenic Bladder Overactivity

  • Idiopathic Bladder Overactivity

By Drug Type

  • Darifenacin

  • Anticholinergics

  • Oxybutynin

  • Solifenacin

  • Others

Customize this Report: Request Customization

Key Companies Dominating the Global Overactive Bladder Treatment Market

Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global overactive bladder treatment market that are included in our report are Bio-Rad Laboratories, Inc., Hologic, Inc., F.Hoffmann-La Roche Ltd, AbbVie Inc, Pfizer Inc., Teva Pharmaceutical Industries Ltd, Thermo Fisher Scientific, Intas Pharmaceuticals Ltd,  Viatris Inc., Hisamitsu Pharmaceutical Co, Inc., and others.

Global Overactive Bladder Treatment Market: Latest Developments

  • April, 2019: Teva Pharmaceutical Industries Ltd announced the launch of generic version of VESIcare tablets for the treatment of overactive bladder in the United States.

  • November, 2018: Hisamitsu Pharmaceutical Co, Inc., announced the acquisition of an approval of manufacturing and marketing permit for OABLOK PATCH in Taiwan.

Key Reasons to Buy Our Report

  • The report covers detailed analysis comprising market share attained by each market segment and its sub-segments.

  • It covers market dynamics including growth drivers, trends, potential opportunities, price trend analysis and challenges that impact the market growth.

  • The report includes detailed company profiles of the major players dominating the market.

  • We use effective research methodologies to calculate the market numbers and provide value-added assessment for overall growth.

  • We provide customized reports as per the clients’ requirement helping them to see possible and unexpected challenges and unforeseen opportunities in order to help them reach their goal.  

   


Geography Analysis:


The report further discusses the market opportunity, compound annual growth rate (CAGR) growth rate, competition, new technology innovations, market players analysis, government guidelines, export and import (EXIM) analysis, historical revenues, future forecasts etc. in the following regions and/or countries:

  • North America (U.S. & Canada) Market Size, Y-O-Y Growth, Market Players Analysis & Opportunity Outlook
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC(Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market Size, Y-O-Y Growth Market Players Analys  & Opportunity Outlook
  • Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
  • Middle East and Africa  (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market Size, Y-O-Y Growth Market Players Analysis & Opportunity Outlook

.

FREQUENTLY ASKED QUESTIONS

Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report
  1. Bio-Rad Laboratories Inc. 
  2. Hologic Inc. 
  3. F.Hoffmann-La Roche Ltd 
  4. AbbVie Inc 
  5. Pfizer Inc. 
  6. Teva Pharmaceutical Industries Ltd 
  7. Thermo Fisher Scientific 
  8. Intas Pharmaceuticals Ltd 
  9. Viatris Inc. 
  10. Hisamitsu Pharmaceutical Co Inc.
Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report

Related Reports

-->